Unbalanced Risk-Benefit Analysis of ADHD Drugs

The Lancet Psychiatry - United Kingdom
doi 10.1016/s2215-0366(18)30334-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Vaccinations: Mandatory or Voluntary? Risk–Benefit Analysis

Dose-Response
Chemical HealthMutagenesisPublic HealthEnvironmentalSafetyToxicologyHealthOccupational Health
2020English

PND3 Risk-Benefit Analysis of Therapy in Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Allogeneic Hematopoietic Cell Transplantation Versus Drugs in Myelofibrosis: The Risk-Benefit Balancing Act

Bone Marrow Transplantation
TransplantationHematology
2010English

Latent Profile Analysis of Neuropsychological Measures to Determine Preschoolers' Risk for ADHD

Journal of Child Psychology and Psychiatry and Allied Disciplines
DevelopmentalMental HealthChild HealthEducational PsychologyPerinatologyPsychiatryPediatrics
2015English

Safety, Tolerability and Risk Benefit Analysis of Tiotropium in COPD

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2008English

Risk and Benefit

Nature
Multidisciplinary
1998English

The Risk/Benefit Profile of Biologic Drugs in Real-World Rheumatology Practice. From ANTARES to MonitorNet

Reumatismo
Rheumatology
2011English

PND9 the Role of Spontaneous Events Databases for Benefit-Risk Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Risk‐Benefit Assessment of Foods

EFSA Journal
VeterinaryMicrobiologyFood ScienceAnimal ScienceParasitologyPlant ScienceZoology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy